# A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC

Source: https://onco.cc/trials/nct05394831/  
OnCo record `nct05394831` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of JIN-A02 in non-small-cell lung cancer, run by J Ints Bio, now recruiting.

## Summary

A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC is a phase 1/2 interventional study registered as NCT05394831 by J Ints Bio, with 150 participants planned, started 2023-07-30 and due to reach its primary completion in 2026-09-30. Interventions recorded: JIN-A02.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05394831
- Phase: 1/2
- Setting: A Phase 1/2, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of JIN-A02 in Patients With EGFR Mutant Advanced Non-small Cell Lung Cancer
- Sponsor: J Ints Bio
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT05394831: https://clinicaltrials.gov/study/NCT05394831

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)

---
JSON: https://onco.cc/api/v1/entities/nct05394831.json